French pharmaceutical giant Sanofi is set to bolster its presence in the Indian market with a focus on introducing new drugs and expanding its existing brands. With plans to enter the premix insulin segment with Soliqua, the company aims to offer tailored options for diabetes management. Sanofi also has a robust pipeline of 12 products slated for launch in India. Additionally, the company intends to collaborate with domestic firms to enhance localisation and production capabilities. With a strategic emphasis on growth, Sanofi is poised to make significant strides in India’s pharmaceutical landscape.